Department of Medical Microbiology and Parasitology, Ladoke Akintola University of Technology, Ogbomosho, Nigeria.
Department of Medical Microbiology and Parasitology, University of Ibadan, Oyo, Nigeria.
Infect Disord Drug Targets. 2021;21(4):595-602. doi: 10.2174/1871526520999200729181559.
Extended Spectrum Beta Lactamase (ESBL) production in gram negative bacteria confers multiple antibiotic resistance, adversely affecting antimicrobial therapy in infected individuals. ESBLs result from mutations in β-lactamases encoded mainly by the bla,bla and bla genes. The prevalence of ESBL producing bacteria has been on the increase globally, especially its upsurge among isolates from community-acquired infections has been observed.
To determine ESBL prevalence and identify ESBL genes among clinical isolates in Osun State, Nigeria.
A cross-sectional study was carried out from August 2016 - July 2017 in Osun State, Nigeria. Three hundred and sixty Gram-negative bacteria recovered from clinical samples obtained from both community and healthcare-associated infections were tested. They included 147 Escherichia coli (40.8%), 116 Klebsiella spp (32.2%), 44 Pseudomonas aeruginosa (12.2%) and 23 Proteus vulgaris (6.4%) isolates. Others were Acinetobacter baumannii, Serratia rubidae, Citrobacter spp, Enterobacter spp and Salmonella typhi. Disk diffusion antibiotic susceptibility testing was carried out, isolates were screened for ESBL production and confirmed using standard laboratory procedures. ESBLs resistance genes were identified by Polymerase Chain Reaction (PCR).
All isolates demonstrated multiple antibiotic resistance. Resistance to ampicillin, amoxicillin with clavulanate and erythromycin was 100%, whereas resistance to Imipenem was very low (5.0%). The overall prevalence of ESBL producers was 41.4% with Klebsiella spp as the highest ESBL producing Enterobacteriacaea. ESBL producers were more prevalent among the hospital pathogens than community pathogens, 58% vs. 29.5% (p=0.003). ESBL genes were detected in all ESBL producers with the bla gene predominating (47.0%) followed by bla (30.9%) and bla gene was the least, 22.1%. The bla gene was also the most prevalent in the healthcare pathogens (62%) but it accounted for only 25% in those of community origin.
A high prevalence of ESBL producing gram-negative organisms occurs both in healthcare and in the community in our environment with the CTX-M variant predominating. Efforts to control the spread of these pathogens should be addressed.
革兰氏阴性菌产生的扩展谱β-内酰胺酶(ESBL)可导致多种抗生素耐药性,从而对感染患者的抗菌治疗产生不利影响。ESBL 是由 bla、bla 和 bla 基因编码的β-内酰胺酶基因突变引起的。全球范围内 ESBL 产生菌的流行率一直在上升,尤其是在社区获得性感染分离株中,其发生率有所上升。
在尼日利亚奥孙州确定临床分离株中 ESBL 的流行率并鉴定 ESBL 基因。
本研究于 2016 年 8 月至 2017 年 7 月在尼日利亚奥孙州进行,共检测了来自社区和医疗相关感染的临床标本中 360 株革兰氏阴性菌。其中包括 147 株大肠埃希菌(40.8%)、116 株肺炎克雷伯菌(32.2%)、44 株铜绿假单胞菌(12.2%)和 23 株普通变形杆菌(6.4%)分离株。其他分离株包括鲍曼不动杆菌、鲁氏不动杆菌、柠檬酸杆菌、肠杆菌属和伤寒沙门氏菌。采用纸片扩散抗生素药敏试验进行检测,采用标准实验室程序对 ESBL 产生情况进行筛查和确证。采用聚合酶链反应(PCR)鉴定 ESBL 耐药基因。
所有分离株均表现出多种抗生素耐药性。对氨苄西林、阿莫西林克拉维酸和红霉素的耐药率为 100%,而对亚胺培南的耐药率很低(5.0%)。ESBL 产生者的总体流行率为 41.4%,其中肺炎克雷伯菌是产 ESBL 的肠杆菌科中最高的。医院病原体中的 ESBL 产生者比社区病原体多,分别为 58%和 29.5%(p=0.003)。所有 ESBL 产生者均检测到 ESBL 基因,其中 bla 基因占主导地位(47.0%),其次是 bla(30.9%),bla 基因最少,占 22.1%。bla 基因在医院病原体中也最为常见(62%),但在社区来源的病原体中仅占 25%。
在我们的环境中,无论是在医疗机构还是社区,都存在高比例的 ESBL 产生革兰氏阴性菌,其中 CTX-M 变体占主导地位。应努力控制这些病原体的传播。